Document is current
Any future updates will be listed below
-
Authors
Furuya, Takefumi https://orcid.org/0000-0001-7771-2813
Oh, Koei https://orcid.org/0000-0002-9061-0771
Ikari, Katsunori https://orcid.org/0000-0001-9066-2005
Inoue, Eisuke https://orcid.org/0000-0002-1652-7769
Tanaka, Eiichi https://orcid.org/0000-0003-2850-326X
Yamanaka, Hisashi https://orcid.org/0000-0001-8453-6731
Harigai, Masayoshi https://orcid.org/0000-0002-6418-2603
-
Funding
Funding for this research was provided by:
asahi kasei pharma corporation
astellas pharma
AbbVie Japan GK
Ayumi Pharmaceutical Corporation
Bristol-Myers Squibb
Chugai Pharmaceutical
Daiichi-Sankyo
Eisai
Kaken Pharmaceutical
Kissei Pharmaceutical
Mitsubishi Tanabe Pharma Corporation
Mochida Pharmaceutical Company
Nippon Kayaku Co.,Ltd
Nippon Shinyaku Co.,Ltd
Pfizer Japan
Sekisui Medical Co.,Ltd
Taisho Toyama Pharmaceutical Company
Takeda Pharmaceutical Company
Teijin Pharma
UCB
- License Information
-
More Information
Article History
Received: 13 June 2021
Revised: 17 September 2021
Accepted: 22 September 2021
First Online: 29 September 2021
Declarations
:
: This study was approved by the ethics committee of Tokyo Women’s Medical University (No. 2922-R16).
: Informed consent was obtained from all patients at entry and before each survey of IORRA.
: Not applicable.
: T.F. has served on speakers’ bureaus for Ayumi Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Inc., and Ono Pharmaceutical Co., Ltd. K.I. has received speaker’s fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma, Ltd., and UCB Japan Co., Ltd. E.I. has received speaker fees from Bristol-Myers Squibb and Pfizer Japan, Inc. E.T. has received lecture/consulting fees from Abbvie, Asahi Kasei Pharma Co., Astellas Pharmaceutical, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai Pharmaceutical, Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kyowa Pharma Chemical Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Pfizer, Takeda Pharmaceutical, and Teijin Pharma Ltd. H.Y. has received speaker fee from Astellas, Bristol-Meyers-Squibb, Eisai, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, YLBio. MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Astra Zeneca K. K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippn Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd and UCB Japan. MH is a consultant for AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma.
